Poly(ADP-ribose) Polymerase Inhibitors: all 983 studies that test it
Page 8 of 10. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- IMP4297 Food Effect Trial in Healthy VolunteersCompletedNCT04057729Phase 1
- Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid TumorsStatus unknownNCT04053673Phase 1
- Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.Active, not recruitingNCT04053322Phase 2
- PARP Inhibition During Pre-surgical Window in Breast/Ovary CancerCompletedNCT04041128Early Phase 1
- Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.Active, not recruitingNCT04039230Phase 1/2
- A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on FluzoparibCompletedNCT04011124Phase 1
- Study of Olaparib and Durvalumab in IDH-Mutated Solid TumorsActive, not recruitingNCT03991832Phase 2
- A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerActive, not recruitingNCT03981796Phase 3
- Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination GenesActive, not recruitingNCT03967938Phase 2
- TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast CancerActive, not recruitingNCT03964532Phase 1/2
- Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall RecurrencesTerminatedNCT03955640Phase 1
- Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral ContraceptivesCompletedNCT03954366Phase 1
- Durvalumab and Olaparib in Metastatic or Recurrent Endometrial CancerStatus unknownNCT03951415Phase 2
- A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer PatientsActive, not recruitingNCT03945721Phase 1
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBCCompletedNCT03945604Phase 1
- Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based ChemotherapyCompletedNCT03945084Phase 2
- CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer PatientsTerminatedNCT03944902Phase 1
- Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before SurgeryActive, not recruitingNCT03943173Early Phase 1
- Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or ChemotherapyWithdrawnNCT03933761Phase 2
- Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast CancerTerminatedNCT03931551Phase 2
- Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) MutationStatus unknownNCT03925350Phase 2
- Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersTerminatedNCT03924245Phase 1
- Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersActive, not recruitingNCT03911973Phase 1/2
- Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast TumorsCompletedNCT03911453Early Phase 1
- A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian CancerStatus unknownNCT03895788Phase 1
- Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung CancerTerminatedNCT03891615Phase 1
- Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)TerminatedNCT03891576Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT03874884Phase 1
- A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer PatientsCompletedNCT03863860Phase 3
- Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid TumorsActive, not recruitingNCT03851614Phase 2
- Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.CompletedNCT03838744Phase 2
- Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line ChemotherapyActive, not recruitingNCT03830918Phase 1/2
- A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric CancerStatus unknownNCT03829345Phase 2
- Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian CancerWithdrawnNCT03806049Phase 3
- FUSCC Refractory TNBC Umbrella (FUTURE)Status unknownNCT03805399Phase 1/2
- Rucaparib Maintenance Therapy in Advanced Cervical CancerWithdrawnNCT03795272Phase 2
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3
- Olaparib for PAH: a Multicenter Clinical TrialTerminatedNCT03782818Phase 1/2
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3
- NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.CompletedNCT03752216Phase 4
- BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV GliomasActive, not recruitingNCT03749187Phase 1
- UTOLA: UTerin OLAparibCompletedNCT03745950Phase 2
- Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast CancerActive, not recruitingNCT03742245Phase 1
- A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian CancerStatus unknownNCT03709316Phase 3
- Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer PatientStatus unknownNCT03705156Phase 3
- A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian CancerCompletedNCT03695380Phase 1
- HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerCompletedNCT03685331Phase 1
- Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsActive, not recruitingNCT03682289Phase 2
- Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung CancerActive, not recruitingNCT03672773Phase 2
- Olaparib + Sapacitabine in BRCA Mutant Breast CancerActive, not recruitingNCT03641755Phase 1
- Niraparib in Patients With Pancreatic CancerCompletedNCT03601923Phase 2
- Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast CancerActive, not recruitingNCT03598257Phase 2
- Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast CancerActive, not recruitingNCT03594396Phase 1/2
- Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03586661Phase 1
- Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric CancerActive, not recruitingNCT03579784Phase 2
- Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03579316Phase 2
- ARQ761 + PARP Inhibitor in Refractory Solid TumorsWithdrawnNCT03575078Phase 1
- Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?Status unknownNCT03570437Phase 2
- Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRPCompletedNCT03562832Phase 2
- Olaparib in Recurrent IDH-mutant GliomaCompletedNCT03561870Phase 2
- Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT03552471Phase 1
- The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian CancerCompletedNCT03551171Phase 1
- Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast CancerCompletedNCT03544125Phase 1
- Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)CompletedNCT03534492Phase 2
- Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyCompletedNCT03534453Phase 3
- Rucaparib Hepatic Impairment Study in Patients With a Solid TumorCompletedNCT03521037Phase 1
- Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian CancerActive, not recruitingNCT03519230Phase 3
- A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung CancerTerminatedNCT03516084Phase 3
- A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian CancerCompletedNCT03509636Phase 1
- A Study of IMP4297 in Patients With Advanced Solid TumorsCompletedNCT03508011Phase 1
- The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid TumorsCompletedNCT03507543Phase 1
- A Study of Rucaparib in Japanese Patients With a Previously-treated Solid TumorCompletedNCT03499444Phase 1
- Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian CarcinomaCompletedNCT03470805Phase 2
- Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva CombinationStatus unknownNCT03462212Phase 1/2
- Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)CompletedNCT03434158Phase 2
- Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]CompletedNCT03428607Phase 2
- Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid TumorsWithdrawnNCT03426254Phase 1
- Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)CompletedNCT03425201Phase 1/2
- A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian CancerWithdrawnNCT03400306Phase 1
- IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOCCompletedNCT03378297Early Phase 1
- Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic ChangesActive, not recruitingNCT03375307Phase 2
- Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast CancerActive, not recruitingNCT03368729Phase 1/2
- A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single AgentTerminatedNCT03367689Phase 2
- Olaparib In Metastatic Breast CancerActive, not recruitingNCT03344965Phase 2
- Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid TumorsCompletedNCT03317743Phase 1
- Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPCCompletedNCT03263650Phase 2
- Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell TransplantCompletedNCT03259503Phase 1
- Olaparib for PAH: a Pilot StudyTerminatedNCT03251872Early Phase 1
- Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2
- Study in Patients With SCLC of Veliparib in Combination With TopotecanStatus unknownNCT03227016Phase 1
- Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas PatientsActive, not recruitingNCT03212742Phase 1/2
- Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor MalignanciesTerminatedNCT03209401Phase 1
- The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid TumorsTerminatedNCT03182673Phase 1
- The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknownNCT03182634Phase 2
- Selumetinib and Olaparib in Solid TumorsActive, not recruitingNCT03162627Phase 1
- Resistant Ovarian Cancer, Olaparib and Liposomal DoxorubicinCompletedNCT03161132Phase 2
- Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid TumorsCompletedNCT03127215Phase 2
- Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian CancerCompletedNCT03117933Phase 2
- Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)CompletedNCT03109080Phase 1